More cases of ALS, Alzheimer鈥檚, Parkinson鈥檚, and other neurodegenerative diseases are being diagnosed each year. As safe and effective treatment options remain severely limited, CSHL leverages expertise in neuroscience and molecular biology to identify hidden drug targets and develop new therapeutic strategies.
鈥� Dianne Larson, whose daughter Emma was diagnosed with the neurodegenerative disease spinal muscular atrophy at the age of 1.
Spinal muscular atrophy (SMA) was once the leading genetic cause of infant death. That鈥檚 no longer the case, thanks in part to Nusinersen (brand name Spinraza). Developed by CSHL Professor Adrian Krainer and colleagues at Ionis Pharmaceuticals and Biogen, Nusinersen is the first FDA-approved treatment for SMA.
Today, more than 14,000 people worldwide have received this revolutionary treatment, built upon CSHL鈥檚 historic discovery of alternative RNA splicing.
Rockefeller University geneticist Jeffrey Friedman speaks about obesity鈥檚 causes and treatments at CSHL鈥檚 Brain-Body Physiology Symposium.
Learn More黑料吃瓜资源 scientists identified the first cancer-causing gene and completed the first genomic profile of multiple individual cancer cells within a single tumor. These breakthroughs鈥攖wo of鈥�
Learn More
Fundamental chemistry at CSHL helped revive a powerful antibiotic against drug-resistant bacteria, opening a new front in the fight against superbugs.
Read Story
Generations of scientific pioneers reflect on the discoveries, collaborations, and risks that have defined their careers.
Read Story
At the 32nd Annual CSHL Golf Tournament, a day of athleticism and camaraderie was also one of generosity.
Read Story
Robertson Research
Fund
Coins for Alzheimer鈥檚
Research Trust
Christine and
Douglas Fox
Estate of
Andre Lacy
The Meier and Linnartz
Family Foundation
Knott Family
Foundation
Heartfelt Wings
Foundation